Chemours (CC) PT Lowered to $20 at Jefferies

Jefferies analyst Laurence Alexander lowered the price target on Chemours (NYSE: CC) to $20.00 (from $21.00) while maintaining a Hold rating.

The analyst comments "Q4 EBITDA of $179 was $14m above both consensus and our estimate. 2025 EBITDA is pegged at $825-$975m (consensus $930m), with a QoQ decline in Q1. A decline in Chinese competitive pressure likely will be a TiO2 tailwind in Europe, and construction demand could strengthen in 2H25-2026. Opteon adoption will also provide some volume growth, amplified by productivity, offsetting soft Freon sales and weakness in APM."

You May Also Be Interested In

• Definium Therapeutics Inc (DFTX) PT Raised to $60 at Oppenheimer
• Macy's (M) PT Raised to $25 at TD Cowen
• Texas AG Paxton announces ongoing investigation into Carnival over data breach